

# Abstract



**James E. Bradner, MD**  
**President - Novartis Institutes for Biomedical Research**

*“New Paths to the Waterfall: Rethinking the Science of Therapeutics for Pediatric Malignancies”*

“Dr. Bradner will discuss the relationship between academia and industry in cancer drug development. He will provide a specific emphasis on pediatric oncology drug development. He will provide relevant examples from his own laboratory work focused on new targets. This will include targets involved in determining structure of chromatin (complex of DNA and proteins that constitute chromosomes) and transcription (converting DNA into an RNA message). A key example will be bromodomain inhibitors, a novel class of drugs with anti-cancer agents now in clinical trials.”